Hospital
Alameda Health System
Alameda Health System was paid $11.52M by Medicaid between Jan 2018 and Dec 2024, across 166 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoALAMEDA HEALTH SYSTEM
ALAMEDA, CA 94501
ALAMEDA, CA 94501
33aNPI1831529049assigned 11/25/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.52M
24GClaims290,009
24DCodes billed166
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#166 of 410
Median peer was paid$6.90M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,687 | $1.30M | |
| 2019 | 25,324 | $1.01M | |
| 2020 | 26,069 | $890K | |
| 2021 | 32,029 | $1.03M | |
| 2022 | 43,965 | $2.14M | |
| 2023 | 59,114 | $2.41M | |
| 2024incomplete | 70,821 | $2.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 32,003 | 28,082 | $1.92M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 7.8% | 7,197 | 2,624 | $894K |
| 99070 | 5.0% | 27,460 | 10,691 | $576K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.6% | 6,051 | 5,514 | $535K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 4.4% | 809 | 803 | $511K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.3% | 1,828 | 1,768 | $492K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.1% | 2,024 | 1,983 | $471K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.2% | 8,052 | 7,451 | $364K |
| J3490 | Unclassified drugs | 2.7% | 17,034 | 7,665 | $307K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.1% | 3,834 | 3,440 | $241K |
| 99199 | Unlisted special service, procedure or report | 2.0% | 3,388 | 2,863 | $227K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.9% | 178 | 178 | $213K |
154 more codes
| 97139 | 1.8% | 11,659 | $210K | |
| 0450 | Emergency room services | 1.8% | 3,604 | $205K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 2,381 | $203K |
| 99221 | 1.7% | 492 | $193K | |
| 72141 | 1.6% | 276 | $189K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 1.5% | 303 | $178K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1.5% | 294 | $171K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.5% | 354 | $170K |
| 80053 | Comprehensive metabolic panel | 1.4% | 13,512 | $163K |
| 99232 | Hospital visit by a doctor, follow-up day | 1.3% | 843 | $154K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 3,475 | $128K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 15,660 | $118K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 760 | $115K |
| 86480 | <1% | 1,461 | $111K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,248 | $111K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,752 | $107K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,409 | $103K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,486 | $97K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,479 | $95K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,498 | $94K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 739 | $80K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 288 | $74K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,835 | $72K |
| 82274 | <1% | 4,355 | $63K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,180 | $63K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 238 | $62K |
| 84484 | <1% | 6,055 | $62K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,934 | $56K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 896 | $49K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,645 | $49K |
| 83690 | <1% | 6,287 | $46K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,701 | $45K |
| 0250 | <1% | 4,457 | $43K | |
| 73221 | <1% | 91 | $42K | |
| 97750 | <1% | 1,007 | $40K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 2,775 | $39K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,152 | $37K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 536 | $37K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 114 | $36K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,088 | $35K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,738 | $33K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,088 | $32K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 390 | $31K |
| 86703 | <1% | 1,752 | $28K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 1,843 | $26K |
| 73030 | <1% | 640 | $23K | |
| 76000 | <1% | 675 | $22K | |
| 86803 | <1% | 1,486 | $22K | |
| 77080 | <1% | 574 | $22K | |
| 83605 | <1% | 1,642 | $21K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 250 | $20K |
| 82962 | <1% | 2,878 | $20K | |
| 81025 | <1% | 5,260 | $20K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,063 | $19K |
| V2632 | Posterior chamber intraocular lens | <1% | 90 | $18K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 580 | $18K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 206 | $18K |
| 81003 | <1% | 8,073 | $17K | |
| 11045 | <1% | 576 | $17K | |
| 87088 | <1% | 2,840 | $16K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 334 | $16K |
| V2630 | Anterior chamber intraocular lens | <1% | 150 | $15K |
| 83880 | <1% | 589 | $14K | |
| 73562 | <1% | 424 | $14K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,402 | $14K |
| 76830 | Ultrasound, transvaginal | <1% | 152 | $14K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,970 | $14K |
| 72100 | <1% | 388 | $12K | |
| 83735 | <1% | 1,665 | $11K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,019 | $11K |
| 73564 | <1% | 295 | $10K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 689 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,103 | $10K |
| 87400 | <1% | 553 | $9K | |
| 87040 | <1% | 603 | $9K | |
| 73630 | <1% | 294 | $8K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,051 | $8K |
| 87081 | <1% | 1,354 | $8K | |
| 81001 | <1% | 2,381 | $8K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 834 | $8K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 243 | $8K |
| 73130 | <1% | 225 | $7K | |
| 70498 | <1% | 25 | $7K | |
| 72170 | <1% | 292 | $7K | |
| 85027 | <1% | 1,030 | $6K | |
| 73610 | <1% | 149 | $6K | |
| 97597 | <1% | 120 | $5K | |
| 87490 | <1% | 194 | $5K | |
| 87634 | <1% | 87 | $5K | |
| 93308 | <1% | 24 | $5K | |
| 84702 | <1% | 430 | $5K | |
| 85610 | <1% | 1,322 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 696 | $5K |
| 85379 | <1% | 415 | $4K | |
| 87590 | <1% | 194 | $4K | |
| 99218 | <1% | 129 | $4K | |
| 87186 | <1% | 594 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 464 | $4K |
| 84466 | <1% | 348 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 506 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 475 | $3K |
| 70496 | <1% | 13 | $3K | |
| 85730 | <1% | 450 | $3K | |
| 87341 | <1% | 295 | $3K | |
| 87077 | <1% | 429 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 322 | $2K |
| J7324 | Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | <1% | 46 | $2K |
| 82803 | <1% | 181 | $2K | |
| 97799 | <1% | 252 | $2K | |
| 73110 | <1% | 60 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 125 | $2K |
| 93971 | <1% | 30 | $2K | |
| 73502 | <1% | 49 | $2K | |
| 85652 | <1% | 672 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 13 | $2K |
| 71020 | <1% | 48 | $2K | |
| Z7502 | <1% | 41 | $1K | |
| 94150 | <1% | 133 | $1K | |
| 99283 | Emergency room visit (moderate) | <1% | 41 | $1K |
| 76536 | <1% | 30 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 185 | $1K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 60 | $1K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 93 | $1K |
| 99152 | <1% | 17 | $1K | |
| 87210 | <1% | 276 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 102 | $1K |
| 90715 | <1% | 24 | $1K | |
| 82375 | <1% | 61 | $968.14 | |
| 90656 | <1% | 24 | $955.88 | |
| 80143 | <1% | 63 | $952.02 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 41 | $807.05 |
| 71010 | <1% | 41 | $781.42 | |
| 80179 | <1% | 38 | $638.58 | |
| 83540 | <1% | 95 | $608.26 | |
| 81015 | <1% | 150 | $557.80 | |
| 64483 | <1% | 27 | $545.02 | |
| 86140 | <1% | 114 | $527.78 | |
| 86850 | <1% | 70 | $417.72 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 68 | $397.00 |
| 86900 | <1% | 84 | $377.65 | |
| 86780 | <1% | 32 | $353.40 | |
| 84439 | <1% | 38 | $343.84 | |
| 86901 | <1% | 72 | $339.38 | |
| 87340 | <1% | 34 | $313.39 | |
| 81002 | <1% | 94 | $313.24 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 15 | $253.92 |
| 80061 | Lipid panel | <1% | 13 | $138.48 |
| 64493 | <1% | 18 | $132.30 | |
| 64484 | <1% | 13 | $76.86 | |
| 86706 | <1% | 15 | $71.25 | |
| 0270 | <1% | 324 | $62.78 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 13 | $58.32 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 15 | $33.50 |
| 0250R | 0% | 417 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNSON, SHARI (VP OF REVENUE CYCLE)
| Provider | Location | Paid |
|---|---|---|
| Alameda Health System | Oakland, CA | $5.26M |
| Alameda Health System | Oakland, CA | $1.72M |
| Alameda Health System | San Leandro, CA | $1.39M |
| Elevate 4:14 LLC | Greeley, CO | $158K |
| Alameda Health System | San Leandro, CA | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.